Merck & Co Analyst Price Targets - Benzinga

Merck & Co Inc

MRKNYSE

Trade with Public

Trade with Public

$149.52

3.192.18%

마지막 업데이트: Nov 2, 7:32 AM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Merck & Co Analyst Price Targets - Benzinga

Merck & Co Analyst Price Targets

Wall Street analyst price targets and consensus rating for Merck & Co (MRK).

Price Target Range — 10 Quarters

Analyst Consensus — 24 Analysts

15Buy

9Hold

Consensus RatingBuy# Analysts24Avg. Consensus PT$146Upside to Avg. PT-2.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$145→$155
Oct 30, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$165→$175
Oct 30, 2026	RBC Capital	Trung Huynh	PT Cut	Sector Perform	$145→$140
Oct 30, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$170→$171
Oct 26, 2026	Barclays	Emily Field	PT Raise	Overweight	$150→$180
Oct 12, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$125→$145
Oct 12, 2026	RBC Capital	Trung Huynh	PT Cut	Sector Perform	$150→$145
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Neutral	$120→$145
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$179→$177
Oct 5, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$150→$165
Sep 29, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$155→$180
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$150→$172
Sep 9, 2026	Leerink Partners	Daina Graybosch	PT Raise	Outperform	$127→$161
Sep 8, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$146→$170
Sep 4, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$150→$170
Aug 25, 2026	Wolfe Research	Alexandria Hammond	PT Raise	Outperform	$155→$180
Aug 25, 2026	Argus Research	Jasper Hellweg	PT Raise	Buy	$145→$170
Aug 21, 2026	Goldman Sachs	Terence Flynn	PT Raise	Buy	$140→$160
Aug 20, 2026	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$142→$170
Aug 20, 2026	UBS	Michael Yee	PT Raise	Buy	$145→$175

Analyst Ratings News

PRO
Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $155

Cantor Fitzgerald analyst Carter Gould maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $145 to $155.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $175

JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $165 to $175.

Benzinga Newsdesk

Merck One of Top Large-Cap Biopharma Picks-Analyst

Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.

Vandana Singh

PRO
RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $140

RBC Capital analyst Trung Huynh maintains Merck & Co (NYSE:MRK) with a Sector Perform and lowers the price target from $145 to $140.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $171

Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $170 to $171.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Merck & Co, Raises Price Target to $180

Barclays analyst Emily Field maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $180.

Benzinga Newsdesk